This article was originally published in Start Up
In normal healing, monocytes differentiate into both regulatory macrophages and profibrotic cells known as M2 macrophages and fibrocytes. During fibrosis, that balance is upset and differentiation favors profibrotic cells. Promedior Inc. is developing pentraxin therapeutics designed to control the initiation and progression of fibrosis across a variety of tissues and organ systems.
You may also be interested in...
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Respiratory Therapies: Moving Beyond Symptomatic Relief," features profiles of Pearl Therapeutics, Protectimmun and Pulmatrix. Plus these Start-Ups Across Health Care: 3WIN, Cianna Medical, GlySure and Promedior.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.